Table 4.
Epidemiological-week consultation counts and psychotropic prescription rates per 1,000 consultations across the pandemic and post-pandemic phases.
| Variable | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase 5 | Phase 6 |
|---|---|---|---|---|---|---|
| 2020: W36 – W53 | 2021: W01 –W33 | 2021: W34–W52 | 2022: W01–W14 | 2022: W15–W52 | 2023: W1–2024: W52 | |
| Number of weeks | 18 | 33 | 19 | 14 | 38 | 104 |
| Total number of consultations | 578 | 1546 | 959 | 669 | 1587 | 4073 |
| Number of consultations per epidemiological week (median [IQR]) | 32 [6] | 46 [12]a****,d** | 52 [14]a****,d*****, c* | 50 [13]a***, d* | 42 [7]a** | 38 [13]a* |
| Prescription rates (median [IQR]) | ||||||
| Overall psychotropics | 1254 [145] | 1318 [167]c*** | 1310 [168] | 1207 [195] | 1199 [239] | 1308 [240]c**** |
| Antipsychotics | 385 [140]c* | 429 [108] | 288 [107]b** | 366 [99] | 296 [121]b**** | 343 [140]b** |
| Antidepressants | 403 [192] | 420 [102]d** | 429 [93] | 384 [123]d* | 370 [116]d**** | 500 [106] |
| Mood stabilizers | 31 [49] | 32 [47] | 32 [21] | 38 [37] | 49 [68] | 33 [65] |
| Anxiolytics | 432 [155] | 444 [144] | 490 [84]d* | 417 [44] | 448 [112] | 413 [157] |
Kruskal–Wallis test with Dunn's post-hoc test. Superscript letters indicate significant pairwise comparisons: a= vs. Phase 1; b= vs. Phase 2; c= vs. Phase 5; d= vs. Phase 6.
Asterisks indicate the level of significance: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
IQR, interquartile range. Prescription rates were calculated as the ratio of the weekly psychotropic prescriptions to the total number of weekly psychiatric consultations, multiplied by 1000.